Literature DB >> 31527035

Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

M Biagi1, D Butler1, X Tan1, S Qasmieh1, K Tejani1, S Patel1,2, R M Rivosecchi3, M H Nguyen4, C J Clancy4,4, R K Shields4,4, E Wenzler5.   

Abstract

The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, mean (± SD) plasma PK parameters of isavuconazole were: C max 4.00±1.45 mg/L, C min 1.76±0.76 mg/L, t ½ 48.36±29.78 h, Vss 288.78±182.11 L, CLss 4.85±3.79 L/h, and AUC 54.01±20.98 mg ⋅ h/L. Transmembrane clearance represented just 0.7% of the total isavuconazole clearance. These data suggest that isavuconazole is not readily removed by CRRT and no dose adjustments are necessary.
Copyright © 2019 American Society for Microbiology.

Entities:  

Year:  2019        PMID: 31527035      PMCID: PMC6879253          DOI: 10.1128/AAC.01085-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Antifungal prophylaxis in lung transplantation--a world-wide survey.

Authors:  C F Neoh; G I Snell; T Kotsimbos; B Levvey; C O Morrissey; M A Slavin; K Stewart; D C M Kong
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration.

Authors:  U F Kroh; H Lennartz; D J Edwards; K Stoeckel
Journal:  J Clin Pharmacol       Date:  1996-12       Impact factor: 3.126

4.  Characterization of butyrylcholinesterase in bovine serum.

Authors:  Alicia J Dafferner; Sofya Lushchekina; Patrick Masson; Gaoping Xiao; Lawrence M Schopfer; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2017-02-08       Impact factor: 5.192

5.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.

Authors:  David Andes; Laura Kovanda; A Desai; Therese Kitt; M Zhao; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

6.  How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin.

Authors:  Brigitte Meyer; Salwa Ahmed el Gendy; Georg Delle Karth; Gottfried J Locker; Gottfried Heinz; Walter Jaeger; Florian Thalhammer
Journal:  Kidney Blood Press Res       Date:  2003       Impact factor: 2.687

7.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

8.  Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.

Authors:  Caitlin R Rausch; Adam J DiPippo; Prithviraj Bose; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

9.  A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.

Authors:  Darren M Roberts; Xin Liu; Jason A Roberts; Priya Nair; Louise Cole; Michael S Roberts; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care       Date:  2015-03-13       Impact factor: 9.097

10.  Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network.

Authors:  Brandon J Webb; Jeffrey P Ferraro; Susan Rea; Stephanie Kaufusi; Bruce E Goodman; James Spalding
Journal:  Open Forum Infect Dis       Date:  2018-07-31       Impact factor: 3.835

View more
  3 in total

1.  Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.

Authors:  Erin K McCreary; M Hong Nguyen; Matthew R Davis; Jared Borlagdan; Ryan K Shields; Anthony D Anderson; Ryan M Rivosecchi; Rachel V Marini; Lauren M Sacha; Fernanda P Silveira; David R Andes; Alexander J Lepak
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

2.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?

Authors:  Frédéric J Baud; Pascal Houzé
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.